JP2013544244A - 抗炎症組成物 - Google Patents

抗炎症組成物 Download PDF

Info

Publication number
JP2013544244A
JP2013544244A JP2013539093A JP2013539093A JP2013544244A JP 2013544244 A JP2013544244 A JP 2013544244A JP 2013539093 A JP2013539093 A JP 2013539093A JP 2013539093 A JP2013539093 A JP 2013539093A JP 2013544244 A JP2013544244 A JP 2013544244A
Authority
JP
Japan
Prior art keywords
interleukin
administration
inflammation
inflammatory
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013539093A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013544244A5 (cg-RX-API-DMAC7.html
Inventor
イン コ，サイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2013544244A publication Critical patent/JP2013544244A/ja
Publication of JP2013544244A5 publication Critical patent/JP2013544244A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
JP2013539093A 2010-11-19 2011-11-09 抗炎症組成物 Pending JP2013544244A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201010551433.8 2010-11-19
CN201010551433.8A CN102462837B (zh) 2010-11-19 2010-11-19 抗炎组合物
PCT/AU2011/001446 WO2012065212A1 (en) 2010-11-19 2011-11-09 Anti-inflammatory compositions

Publications (2)

Publication Number Publication Date
JP2013544244A true JP2013544244A (ja) 2013-12-12
JP2013544244A5 JP2013544244A5 (cg-RX-API-DMAC7.html) 2014-12-25

Family

ID=46067145

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013539093A Pending JP2013544244A (ja) 2010-11-19 2011-11-09 抗炎症組成物

Country Status (12)

Country Link
US (1) US9289493B2 (cg-RX-API-DMAC7.html)
EP (1) EP2640411B1 (cg-RX-API-DMAC7.html)
JP (1) JP2013544244A (cg-RX-API-DMAC7.html)
KR (1) KR101989201B1 (cg-RX-API-DMAC7.html)
CN (1) CN102462837B (cg-RX-API-DMAC7.html)
AU (1) AU2011331901B2 (cg-RX-API-DMAC7.html)
CA (1) CA2817996C (cg-RX-API-DMAC7.html)
DK (1) DK2640411T3 (cg-RX-API-DMAC7.html)
MX (1) MX348794B (cg-RX-API-DMAC7.html)
MY (1) MY174797A (cg-RX-API-DMAC7.html)
RU (1) RU2627451C9 (cg-RX-API-DMAC7.html)
WO (1) WO2012065212A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019529390A (ja) * 2016-09-15 2019-10-17 スキンテック ライフ サイエンス リミテッド 皮膚疾患の処置のためのｄｉｍの舌下又は頬側の投与
JP2024073451A (ja) * 2015-02-25 2024-05-29 アウトセンス ダイアグノスティクス リミテッド 人体排泄物の解析

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9669071B2 (en) 2011-03-11 2017-06-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for stimulating T lymphocytes with IL-2
AU2012228418B2 (en) * 2011-03-11 2016-09-29 Assistance Publique - Hopitaux De Paris Use of low dose IL-2 for treating autoimmune - related or inflammatory disorders
NL2009794C2 (nl) 2012-11-13 2014-05-14 Hevorma B V Groei-inrichting voor gewas, gebruik van een dergelijke inrichting, en een reeks groei-inrichtingen.
EP3180020B1 (en) 2014-08-11 2018-12-26 Delinia, Inc. Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
US11077172B2 (en) 2016-11-08 2021-08-03 Delinia, Inc. IL-2 variants for the treatment of psoriasis
PH12022550165A1 (en) 2019-07-26 2023-05-08 Visterra Inc Interleukin-2 agents and uses thereof
CN115427437B (zh) * 2020-03-31 2024-04-19 韩美药品株式会社 新型免疫刺激il-2类似物
US12098178B2 (en) 2020-12-04 2024-09-24 Visterra, Inc. Methods of using interleukin-2 agents

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02500669A (ja) * 1986-08-18 1990-03-08 エミスフィア・テクノロジーズ・インコーポレイテッド 薬物送達システム
JPH04230222A (ja) * 1990-06-21 1992-08-19 Furant Edith サイトカイン含有エーロゾル剤
WO1999018992A1 (en) * 1997-10-10 1999-04-22 Pharma Pacific Pty. Ltd. Oromucosal cytokine compositions and uses thereof
JP2000510122A (ja) * 1996-05-07 2000-08-08 コーネル リサーチ ファンデーション インク． 低用量ｉｌ―２による免疫応答の刺激
JP2002532556A (ja) * 1998-12-22 2002-10-02 シェリング・コーポレーション Ｃ型肝炎ウイルス感染のインターロイキン−１０での処置
JP2008527988A (ja) * 2005-01-25 2008-07-31 ユニヴァーシティ・オヴ・リーズ 腸内細菌による生物活性物質の制御された産生および送達
WO2008109953A1 (en) * 2007-03-14 2008-09-18 Sai Ying Ko Method for treating cancer via the mucosal administration of interleukin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7361331B2 (en) 1996-10-18 2008-04-22 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food Plant bioreactors
JP4023863B2 (ja) 1997-03-13 2007-12-19 アプライド・リサーチ・システムズ・エイアールエス・ホールディング・ナムローゼ・フェンノートシャップ Ｉｌ−６を含む血清尿酸値低下剤
US6974590B2 (en) 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
DE60038304T3 (de) 1999-09-09 2017-04-06 Merck Sharp & Dohme Corp. Interleukin-12 p40 und interleukin-b30. kombinationen davon. antikörper. verwendungen in pharmazeutische zusammensetzungen
AUPR272901A0 (en) 2001-01-25 2001-02-22 Gainful Plan Limited Method of preparing biological materials and preparations produced using same
EP1545474A1 (en) * 2002-09-16 2005-06-29 Wyeth Delayed release formulations for oral administration of a polypeptide therapeutic agent and methods of using same
CN102174111B (zh) * 2011-01-25 2013-01-09 江苏省弗泰生物科技有限公司 人白介素2-Fc融合蛋白及其用途

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02500669A (ja) * 1986-08-18 1990-03-08 エミスフィア・テクノロジーズ・インコーポレイテッド 薬物送達システム
JPH04230222A (ja) * 1990-06-21 1992-08-19 Furant Edith サイトカイン含有エーロゾル剤
JP2000510122A (ja) * 1996-05-07 2000-08-08 コーネル リサーチ ファンデーション インク． 低用量ｉｌ―２による免疫応答の刺激
WO1999018992A1 (en) * 1997-10-10 1999-04-22 Pharma Pacific Pty. Ltd. Oromucosal cytokine compositions and uses thereof
JP2002532556A (ja) * 1998-12-22 2002-10-02 シェリング・コーポレーション Ｃ型肝炎ウイルス感染のインターロイキン−１０での処置
JP2008527988A (ja) * 2005-01-25 2008-07-31 ユニヴァーシティ・オヴ・リーズ 腸内細菌による生物活性物質の制御された産生および送達
WO2008109953A1 (en) * 2007-03-14 2008-09-18 Sai Ying Ko Method for treating cancer via the mucosal administration of interleukin

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6015032793; Ｊｏｕｒｎａｌ　ｏｆ　Ｂｉｏｍｅｄｉｃｉｎｅ　ａｎｄ　Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｖｏｌ．２０１０, 2010, Ａｒｔｉｃｌｅ　ＩＤ　４６１６４１ *
JPN6015032795; Ａｎｔｉｍｉｃｒｏｂｉａｌ　Ａｇｅｎｔｓ　ａｎｄ　Ｃｈｅｍｏｔｈｅｒａｐｙ Ｖｏｌ．３７，　Ｎｏ．１２, 1993, ｐ．２６８８-２６９２ *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024073451A (ja) * 2015-02-25 2024-05-29 アウトセンス ダイアグノスティクス リミテッド 人体排泄物の解析
JP2019529390A (ja) * 2016-09-15 2019-10-17 スキンテック ライフ サイエンス リミテッド 皮膚疾患の処置のためのｄｉｍの舌下又は頬側の投与
JP7169591B2 (ja) 2016-09-15 2022-11-11 スキンテック ライフ サイエンス リミテッド 皮膚疾患の処置のためのｄｉｍの舌下又は頬側の投与

Also Published As

Publication number Publication date
CN102462837B (zh) 2016-08-03
WO2012065212A1 (en) 2012-05-24
EP2640411B1 (en) 2017-12-20
AU2011331901B2 (en) 2015-01-22
EP2640411A4 (en) 2013-11-20
CA2817996A1 (en) 2012-05-24
DK2640411T3 (en) 2018-04-03
CN102462837A (zh) 2012-05-23
CA2817996C (en) 2019-10-15
RU2627451C2 (ru) 2017-08-08
US20130315859A1 (en) 2013-11-28
KR20140009262A (ko) 2014-01-22
MY174797A (en) 2020-05-15
US9289493B2 (en) 2016-03-22
MX2013005641A (es) 2014-02-06
MX348794B (es) 2017-06-29
RU2627451C9 (ru) 2017-09-29
AU2011331901A1 (en) 2013-04-18
EP2640411A1 (en) 2013-09-25
RU2013127793A (ru) 2014-12-27
KR101989201B1 (ko) 2019-06-13

Similar Documents

Publication Publication Date Title
RU2627451C2 (ru) Противовоспалительные композиции
JP7590724B2 (ja) 炎症性腸疾患の治療薬
JP2961045B2 (ja) 腸管粘膜増強促進剤
TWI241192B (en) Topical formulations for delivery of interleukin-11
JP2005503340A (ja) 口腔および食道病変の治療のための方法および組成物
KR20090045416A (ko) Ｈｇｈ를 포함하는 경구 전달용 제약 조성물
CN102711796A (zh) Prg4及其治疗调制的应用和用途
TW200538466A (en) Methods for controlling angiogenesis and cell proliferation
CN1997383B (zh) 含水母发光蛋白的组合物及使用它的方法
ES2322605T3 (es) Tratamiento de la mucositis oral e intestinal mediante la administracion de il-18 humano.
Kwan et al. Short-term administration of SMS 201-995 in the management of an external pancreatic fistula.
JP2020519658A (ja) 長時間作用性グラチラマー及び脂肪由来幹細胞での多発性硬化症の治療
AU2008226337B2 (en) Method for treating cancer via the mucosal administration of interleukin
EP4566618A1 (en) Nucleic acid encoding klotho for use in therapeutic and non-therapeutic methods for reducing body weight
WO2020058827A1 (en) Oral transmucosal immunotherapy
US20250235506A1 (en) Chimeric il-10/carrier constructs for treatment of pouchitis and methods of use
JP2020527573A (ja) 強皮症関連血管障害を治療または改善するための組成物および方法
JP2875541B2 (ja) 血行再建術後の再閉塞防止剤
CN1929854B (zh) 肺泡的分化诱导或再生诱导制剂
JP2007511540A (ja) 肥満の処置のためおよび体重減少の促進のためのインターフェロンτの使用
WO2025208818A1 (zh) 治疗下肢外周动脉疾病的核酸分子、药物组合物及其应用
WO2025109173A1 (en) Nucleic acid encoding klotho for use in therapeutic and non-therapeutic methods for reducing body weight
CN121177481A (zh) Sirt1激活剂在制备抗炎免疫药物中的应用
CN119215076A (zh) 一种药物组合物及其用途
CN113768865A (zh) 一种抑制炎症因子释放治疗痛风急性发作的聚合物微针及制备方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141107

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150724

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151112

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160412